Presentation is loading. Please wait.

Presentation is loading. Please wait.

C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by.

Published byAlvin Gibbs Modified over 8 years ago

Similar presentations

Presentation on theme: "C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by."— Presentation transcript:

1 C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by Chiron TMA HIV-1/HCV assay Analytical sensitivity of Chiron TMA HIV-1/HCV assay on different HIV-1 subtypes

2 C H I R O N Blood Testing RSA Blood Donation Approximately one million units collected annually – 57% by SABTS (Johannesburg), 18% by NBTS (Durban), 14% by WPBTS (Cape Town), 11% by four other Centers – 90% from “Low-Risk” donors, 10% from “High-Risk” donors High HIV prevalence: overall 0.21% (1997-1998) – Repeat donors 8.7/10,000, first-time donors: 110/10,000 – “Low-Risk” donors: 1.6/10,000, “High-Risk” donors: 196/10,000 – Risk of transfusion-transmission estimated 0.22/10,000 (1994) Donor selection and routine blood testing – Voluntary with self-exclusion questionnaire, face-to-face interview – HIV-1/2 Ab, HIV-1 p24, HCV Ab, HBsAg, syphilis serology – Double EIA testing strategy

3 C H I R O N Blood Testing RSA Study: Study Design All seven Centers collecting voluntary blood donations participated 10,000 “Low-Risk” donors and 10,000 “High-Risk” donors Sample contribution proportional to collection volume Two EDTA plasma tubes shipped frozen to NAT laboratory at SABTS (Johannesburg) for individual TMA testing Routine serology results and donor demographic information collected prior to linkage breaking and TMA testing All positive samples shipped to BCP for additional testing

4 C H I R O N Blood Testing RSA Study: Donor Population TotalRepeatFirst time numberdonorsdonors “Low-Risk” Male 6096 5465 631 Female 3467 3038 429 Total 9563 (46%) 85031060 “High-Risk” Male 6679 5720 959 Female 4378 33341044 Total11057 (54%) 90542003 TOTALMale12775 (62%)111851590 Female 7845 (38%) 63721473 Total20620 (100%)17557 (85%)3063 (15%)

5 C H I R O N Blood Testing RSA Study: Results TMARRRRRRRRNRNR p24 AgNRRRRRNRNRNR AntibodyNRNRRRRRRRNR “Low-Risk” Male000 206094 Female000 103466 Total0 0 0 309560 “High-Risk” Male015 5806615 Female101 9714278 Total1 16 1551 10893 TOTALMale015 600 12709 Female101 981 7744 Total116 1581 20453

6 C H I R O N Blood Testing RSA Study: Preliminary Conclusions The number of HIV specimens identified in the RNA-window (1) and the p24-window (1) is lower than what was anticipated. The role of routine HIV p24 antigen testing should be re-evaluated. Automation and cost might be factors that will influence the decision on whether or not to do routine NAT testing. Nel TJ, et al. Abstract accepted by AABB 2000 for oral presentation

7 C H I R O N Blood Testing Genomic Detection of HIV by TMA in High Prevalence Areas of Sub-Saharan Africa PoolPoolsDonors Pos. TMA p24Ab sizetestedtested pools pos. pos. pos. S. Africa 24126 3024 4 4 4 b 0 Ghana 11-25140 2578 10 c 8 a 0 6 b a Two TMA-positive / seronegative samples were confirmed by RT-PCR. b Included as positive controls. C Two contained HCV-pos samples, one with TMA-neg samples, one with QNSs. Allain JP, et al., abstract accepted by AABB 2000 for oral presentation

8 C H I R O N Blood Testing HIV-1 p24 Antigen Positive Donations a,b AIBC (4/99 - 8/00) Sample Date TMA Multiplex TMA Disc HIV Serology ID Received Pool Single HIV-1 p24/Neut Ab/WB SF07989444 07/09/99 19.7 19.018.8 R/P R/N SF08012675 08/27/99 17.1 17.615.5 R/P R/P MM00124739 Sep 99 NT 17.018.6 R/P R/N SF08051578 12/17/99 21.5 22.421.7 R/P R/P SF08063998 02/01/00 19.6 20.220.0 R/P R/P SF08107307 04/04/00 18.6 21.120.1 R/P R/P a Total tested: approximate 600,000 donations. b Data provided by Dr. Richard Gammon, South Florida Blood Banks.

9 C H I R O N Blood Testing Detection of HIV-1 Type A Specimens by TMA Assay SubtypeCopies/ml Origin DetectionSourceTesting Site A29000 2/2Necker ARN 99Lille, FR; Montpllier, FR A15000 2/2Necker ARN 99Lille, FR; Montpllier, FR A7200 2/2Necker ARN 99Lille, FR; Montpllier, FR A6000 Uganda 2/2BBI WWRB302 BBI/Chiron A4600 2/2Necker ARN 99Lille, FR; Montpllier, FR A2300 2/2Necker ARN 99Lille, FR; Montpllier, FR A600 Ghana 2/2BBI WWRB302BBI/Chiron A500 Ghana 2/2BBI WWRB302 BBI/Chiron A200 Ivory Coast 2/2BBI WWRB302 BBI/Chiron A600 Uganda 1/1 at 1:5BBI WWRB301 Chiron A1000 Uganda 1/1 at 1:100BBI WWRB301 Chiron A1000 Ghana 1/1 at 1:100BBI WWRB301 Chiron A600 Ghana 1/1 at 1:100BBI WWRB301 Chiron A< 400 Ghana 1/1 at 1:100BBI WWRB301 Chiron A< 50 Uganda 1/1 at 1:5BBI WWRB301 Chiron A< 50 Ghana 1/1 at 1:100BBI WWRB301 Chiron

10 C H I R O N Blood Testing Detection of HIV-1 Type B Specimens by TMA Assay SubtypeCopies/ml Origin Detection Source Testing Site B30000 2/2 Necker ARN 99 Lille, FR; Montpllier, FR B20000 USA 2/2 BBI WWRB302 BBI/Chiron B8200 2/2 Necker ARN 99Lille, FR; Montpllier, FR B/D5000 USA 2/2 BBI WWRB302 BBI/Chiron B3700 2/2 Necker ARN 99Lille, FR; Montpllier, FR B2000 China 2/2 BBI WWRB302 BBI/Chiron B1800 2/2 Necker ARN 99Lille, FR; Montpllier, FR B900 Argentina 2/2 BBI WWRB302 BBI/Chiron B40000 Egypt 1/1 at 1:100 BBI WWRB301 Chiron B20000 China 1/1 at 1:100 BBI WWRB301 Chiron B100 160/160 WHO StandardGen-Probe B100 5/5 VQA 003ruLille, FR B100 20/20 VQA PanelHokkaido, JP

11 C H I R O N Blood Testing Detection of HIV-1 Type B Specimens by TMA Assay SubtypeCopies/ml Origin DetectionSource Testing Site B9000 RSA 1/1 at 1:100BBI WWRB301 Chiron B6000 China 1/1 at 1:100BBI WWRB301 Chiron B50 6/6VQA 003ru Lille, FR B50 19/20VQA Panel Hokkaido, JP B5000 China 1/1 at 1:100BBI WWRB301 Chiron B5000 USA 1/1 at 1:100BBI WWRB301 Chiron B4000 China 1/1 at 1:100BBI WWRB301 Chiron B30 155/160WHO Standard Gen-Probe B25 2/2Pelicheck S2091 Lyon, FR B20 20/20JRC Standard Panel Hokkaido, JP B10 20/20JRC Standard Panel Hokkaido, JP B8 2/2Pelicheck S2091 Lyon, FR B200 China 1/1 at 1:100BBI WWRB301 Chiron

12 C H I R O N Blood Testing Detection of HIV-1 Type C Specimens by TMA Assay SubtypeCopies/ml Origin Detection Source Testing Site C70000 Mozanbique 2/2 BBI WWRB302 BBI/Chiron C20000 Uganda 2/2 BBI WWRB302 BBI/Chiron C9300 2/2 Necker ARN 99 Lille, FR; Montpllier, FR C80000 Zimbabwe 1/1 at 1:100 BBI WWRB301 Chiron C 700 Zimbabwe 2/2 BBI WWRB302 BBI/Chiron C390 2/2 Necker ARN 99 Lille, FR; Montpllier, FR C300 Zimbabwe 2/2 BBI WWRB302 BBI/Chiron C30000 RSA 1/1 at 1:100 BBI WWRB301 Chiron C30000 India 1/1 at 1:100 BBI WWRB301 Chiron C700 RSA 1/1 at 1:5 BBI WWRB301 Chiron C4000 Zimbabwe 1/1 at 1:100 BBI WWRB301 Chiron C3000 India 1/1 at 1:100 BBI WWRB301 Chiron C2000 Zimbabwe 1/1 at 1:100 BBI WWRB301 Chiron C< 50 RSA 1/1 at 1:100 BBI WWRB301 Chiron C< 50 Zimbabwe 1/1 at 1:100 BBI WWRB301 Chiron

13 C H I R O N Blood Testing Detection of HIV-1 Type D Specimens by TMA Assay SubtypeCopies/ml Origin DetectionSourceTesting Site D50000 Uganda 2/2BBI WWRB302 BBI/Chiron D10000 Uganda 2/2BBI WWRB302 BBI/Chiron D4800 2/2Necker ARN 99Lille, FR; Montpllier, FR D3000 Uganda 2/2BBI WWRB302 BBI/Chiron D800 Uganda 2/2BBI WWRB302 BBI/Chiron D490 2/2Necker ARN 99Lille, FR; Montpllier, FR D7000 Uganda 1/1 at 1:100BBI WWRB301 Chiron D3000 Uganda 1/1 at 1:100BBI WWRB301 Chiron D1000 Uganda 1/1 at 1:100BBI WWRB301 Chiron D< 50 Uganda 1/1 at 1:5BBI WWRB301 Chiron

14 C H I R O N Blood Testing Detection of HIV-1 Type E Specimens by TMA Assay SubtypeCopies/ml Origin DetectionSourceTesting Site E7700 2/2Necker ARN 99Lille, FR; Montpllier, FR E3000 Thailand 2/2BBI WWRB302 BBI/Chiron E1500 2/2Necker ARN 99Lille, FR; Montpllier, FR E300 Thailand 2/2BBI WWRB302 BBI/Chiron E100 20/20VQA PanelHokkaido, JP E10000 Thailand 1/1 at 1:100BBI WWRB301 Chiron E50 20/20VQA PanelHokkaido, JP E20 19/20VQA PanelHokkaido, JP E< 50 Thailand 2/2BBI WWRB302 BBI/Chiron E< 50 Thailand 1/1 at 1:5BBI WWRB301 Chiron E< 50 Thailand 1/1 at 1:20BBI WWRB301Chiron

15 C H I R O N Blood Testing Detection of HIV-1 Types F,G,H,O Specimens by TMA Assay SubtypeCopies/ml Origin DetectionSourceTesting Site F48000 2/2Necker ARN 99Lille, FR; Montpllier, FR F5900 2/2Necker ARN 99Lille, FR; Montpllier, FR F200 Argentina 2/2BBI WWRB302 BBI/Chiron F10000 Argentina 1/1 at 1:100BBI WWRB301 Chiron F9000 Argentina 1/1 at 1:100BBI WWRB301Chiron F< 50 Argentina 1/1 at 1:5BBI WWRB301Chiron G 48000 2/2Necker ARN 99Lille, FR; Montpllier, FR G3100 2/2Necker ARN 99Lille, FR; Montpllier, FR G< 50 Ghana 1/1 at 1:10BBI WWRB301 Chiron H9500 2/2Necker ARN 99Lille, FR; Montpllier, FR H1400 2/2Necker ARN 99Lille, FR; Montpllier, FR O<150 2/2Necker ARN 99Lille, FR; Montpllier, FR O< 50 Spain 2/2BBI WWRB302 BBI/Chiron O< 50 Cameroon 1/1 at 1:100BBI WWRB301 Chiron

16 C H I R O N Blood Testing Detection of Specimens a with Different HIV-1 Genotypes by TMA Assay (Montpellier, France) Genotype b OriginDetectionGenotype b OriginDetection A/E/- Cambodia1/1-/A/AG Cameroon1/1 A/E/- Cambodia1/1-/A/G Cameroon1/1 A/E/- Cambodia1/1F1/F1/F1 Chad1/1 -/D/F3 Cameroon1/1-/A/G RCA1/1 -/A?/D Cameroon1/1C/C/- Djibouti1/1 -/D/D Cameroon1/1C/C/- Djibouti1/1 -/D/D Djibouti1/1-/O/O Cameroon1/1 F3/F3/F3 Cameroon1/1-/O/O Cameroon1/1 F2/F2/F2 Cameroon1/1-/B/- Montpellier1/1 F2/F2/F2 Cameroon1/1-/A/AG Cameroon1/1 -/G/G Cameroon1/1A/A/J Cameroon1/1 C/C/- Djibouti1/1A/A/- Djibouti1/1 -/A/AG Cameroon1/1A/A/- RCA1/1 a ETSLR Panel, viral loads unknown b gag/pol/env

17 C H I R O N Blood Testing CONCLUSIONS Of the three studies, all 17 HIV-1 p24 antigen positive specimens were also positive in Chiron TMA HIV-1/HCV assay Chiron TMA HIV-1/HCV assay has a  95% detectability at 100 copies/ml for all HIV-1 subtypes

Download ppt "C H I R O N Blood Testing Blood Products Advisory Committee 67th Meeting – September 14, 2000 Detection of HIV-1 p24 antigen positive donor specimens by."

Similar presentations

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Nick Curry, MD, MPH Infectious Diseases Prevention Section
High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.

High Throughput Donor Plasma NAT Screening Assay Applied to Acute HIV Detection in a Public Health Setting December 5, 2007 Josh Goldsmith, Ph.D. National.
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.

Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
HIV-1/HIV-2 PLUS O To detect HIV Antibody Groups M & O Genetic Systems™ HIV-1/HIV-2 PLUS O EIA   HIV Subtypes and Variants   Description of HIV-1/HIV-2.

HIV-1/HIV-2 PLUS O To detect HIV Antibody Groups M & O Genetic Systems™ HIV-1/HIV-2 PLUS O EIA   HIV Subtypes and Variants   Description of HIV-1/HIV-2.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.

Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.
Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.

Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.
Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.

Simplification, cost-reduction strategies and examples from the field Teri Roberts Diagnostics Advisor Médecins Sans Frontières, Access Campaign 7th.
Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.
Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.

Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013.
Vironostika® HIV-1 Plus O Microelisa System

Vironostika® HIV-1 Plus O Microelisa System
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:

Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
F. Kourgia, M. Vini, E. Zervou

F. Kourgia, M. Vini, E. Zervou
Trends in HIV prevalence and HIV incidence in South Africa Thomas M. Rehle, MD, PhD Human Sciences Research Council (HSRC) Cape Town, South Africa AIDS.

Trends in HIV prevalence and HIV incidence in South Africa Thomas M. Rehle, MD, PhD Human Sciences Research Council (HSRC) Cape Town, South Africa AIDS.
Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, 28-29 May, 2009, Brussels, Belgium.

Screening for HBsAg and Anti-HBc in North American Blood Donors John Saldanha, Roche Molecular Systems SoGAT XXI, May, 2009, Brussels, Belgium.
Management of Risk and Blood Availability in Donor Populations with High Prevalence of Blood Borne Pathogens Ravi Reddy IBSF Meeting 20 March 2015.

Management of Risk and Blood Availability in Donor Populations with High Prevalence of Blood Borne Pathogens Ravi Reddy IBSF Meeting 20 March 2015.
Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.

Prevalence and risk relationships of tattoo, acupuncture and skin/body piercing histories among American Red Cross blood donors Sharyn Orton, MSPH, PhD.
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.

E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.
ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV (WWW.ICBS-WEB.ORG) Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.

ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.

Similar presentations

Ads by Google